GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Quick Ratio
中文

Nymox Pharmaceutical (Nymox Pharmaceutical) Quick Ratio : 0.25 (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Nymox Pharmaceutical's quick ratio for the quarter that ended in Sep. 2023 was 0.25.

Nymox Pharmaceutical has a quick ratio of 0.25. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Nymox Pharmaceutical's Quick Ratio or its related term are showing as below:

NYMXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.73   Max: 7.97
Current: 0.25

During the past 13 years, Nymox Pharmaceutical's highest Quick Ratio was 7.97. The lowest was 0.07. And the median was 0.73.

NYMXF's Quick Ratio is ranked worse than
93.56% of 1553 companies
in the Biotechnology industry
Industry Median: 3.56 vs NYMXF: 0.25

Nymox Pharmaceutical Quick Ratio Historical Data

The historical data trend for Nymox Pharmaceutical's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Quick Ratio Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.43 2.60 1.96 0.56 0.69

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 0.69 0.19 0.07 0.25

Competitive Comparison of Nymox Pharmaceutical's Quick Ratio

For the Biotechnology subindustry, Nymox Pharmaceutical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Quick Ratio falls into.



Nymox Pharmaceutical Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Nymox Pharmaceutical's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.457-0)/2.107
=0.69

Nymox Pharmaceutical's Quick Ratio for the quarter that ended in Sep. 2023 is calculated as

Quick Ratio (Q: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.654-0)/2.571
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Nymox Pharmaceutical Quick Ratio Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

May 2023 Market Cap Requirement Update

By GlobeNewswire GlobeNewswire 11-25-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GuruFocusNews GuruFocusNews 11-15-2021

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

NYMOX Provides Shareholder Update

By Marketwired Marketwired 09-10-2021

NYMOX Update

By Marketwired 07-07-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022